Brokers Issue Forecasts for SLN Q1 Earnings

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) – Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Silence Therapeutics in a research note issued to investors on Wednesday, June 17th. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.39) per share for the quarter. HC Wainwright has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Silence Therapeutics’ Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.39) EPS and Q4 2027 earnings at ($0.45) EPS.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Tuesday, April 21st. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a report on Monday, March 2nd. Finally, Jefferies Financial Group raised Silence Therapeutics to a “strong-buy” rating in a report on Wednesday, March 18th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $55.00.

Silence Therapeutics Price Performance

Shares of Silence Therapeutics stock opened at $6.76 on Thursday. The stock has a market cap of $319.34 million, a PE ratio of -4.25 and a beta of 1.48. The firm has a fifty day moving average price of $6.76 and a 200 day moving average price of $6.10. Silence Therapeutics has a 1 year low of $4.19 and a 1 year high of $8.40.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.14). The business had revenue of $0.42 million for the quarter, compared to analyst estimates of $1.26 million. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. EHP Funds Inc. acquired a new stake in shares of Silence Therapeutics during the 3rd quarter valued at about $55,000. XTX Topco Ltd purchased a new position in Silence Therapeutics during the fourth quarter worth approximately $71,000. China Universal Asset Management Co. Ltd. boosted its position in Silence Therapeutics by 65.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock worth $83,000 after purchasing an additional 5,421 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Silence Therapeutics in the third quarter valued at approximately $112,000. Finally, Massar Capital Management LP acquired a new stake in Silence Therapeutics in the second quarter valued at approximately $115,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.